Patient Educ Couns 2020 Jan 10
Improving disease knowledge of primary sclerosing cholangitis patients and their relatives with a 3-dimensional education video.
van Munster KN, van Mil J, Safer R, Nieuwkerk PT, Ponsioen CY
Primary sclerosing cholangitis is a severe liver disease. Liver transplantation is the only curative therapeutic option. The unpredictable disease cou ...
Read More
Source: PubMed
Gut 2020 Jan 28
TGF-ß2 silencing to target biliary-derived liver diseases.
Dropmann A, Dooley S, Dewidar B, Hammad S, Dediulia T, Werle J, Hartwig V, Ghafoory S, Woelfl S, Korhonen H, Janicot M, Wosikowski K, Itzel T, Teufel A, Schuppan D, Stojanovic A, Cerwenka A, Nittka S, Piiper A, Gaiser T, Beraza N, Milkiewicz M, Milkiewicz P, Brain JG, Jones DEJ, Weiss TS, Zanger UM, Ebert M, Meindl-Beinker NM
TGF-ß2 (TGF-ß, transforming growth factor beta), the less-investigated sibling of TGF-ß1, is deregulated in rodent and human liver diseases. Former da ...
Read More
Source: PubMed
Prz Gastroenterol
Inflammatory bowel disease - one entity with many molecular faces.
Szymanska S, Matuszczyk M, Osuch M, Meglicka M, Szymanska E, Bierla J, Kierkus J
Inflammatory bowel disease (IBD) is a heterogenous group of chronic inflammations in the gastrointestinal tract, which traditionally consists of two t ...
Read More
Source: PubMed
World J. Gastroenterol.
Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review.
Onoyama T, Takeda Y, Yamashita T, Hamamoto W, Sakamoto Y, Koda H, Kawata S, Matsumoto K, Isomoto H
Programmed cell death-1 (PD-1) inhibitor has been indicated for many types of malignancies. However, these inhibitors also cause immune-related advers ...
Read More
Source: PubMed
